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A bioactive peptide analogue for myxoma virus
protein with a targeted cytotoxicity for human
skin cancer in vitro
Nahlah M Almansour1,3, Elena Pirogova2,3, Peter J Coloe1, Irena Cosic2 and Taghrid S Istivan1,3*
Abstract
Background: Cancer is an international health problem, and the search for effective treatments is still in progress.
Peptide therapy is focused on the development of short peptides with strong tumoricidal activity and low toxicity.
In this study, we investigated the efficacy of a myxoma virus peptide analogue (RRM-MV) as a candidate for skin
cancer therapy. RRM-MV was designed using the Resonant Recognition Model (RRM) and its effect was examined
on human skin cancer and normal human skin cells in vitro.
Methods: Cell cultures were treated with various concentrations of the peptides at different incubation intervals.
Cellular morphological changes (apoptosis and necrosis) were evaluated using confocal laser scanning microscopy.
The cytotoxic effects of RRM-MV on human skin cancer and normal human skin cells were quantitatively
determined by cytotoxicity and cell viability assays. The effect on human erythrocytes was also determined using
quantitative hemolysis assay. DNA fragmentation assay was performed to detect early apoptotic events in treated
cancer cells. Furthermore, to investigate the possible cell signalling pathway targeted by the peptides treatment,
the levels of p-Akt expression in skin cancer and normal cells were detected by immunoblotting.
Results: Our results indicate that RRM-MV has a dose-dependent toxic effect on cancer cells only up to 18 h. The
immunoblotting results indicated that the RRM-MV slightly increased p-Akt expression in melanoma and carcinoma
cells, but did not seem to affect p-Akt expression in normal skin cells.
Conclusions: RRM-MV targets and lethally harms cancer cells and leaves normal cells unharmed. It is able to reduce
the cancer cell viability, disrupting the LDH activity in cancer cells and can significantly affect cancer progression.
Further investigation into other cell signalling pathways is needed in the process leading to the in vivo testing of
this peptide to prove its safety as a possible effective treatment for skin cancer.
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Background
Cancer is one of the leading causes of death worldwide.
Its occurrence, including in developed countries, is in-
creasing [1]. Although current treatment regimens, such
as chemotherapy, immunotherapy, radiation therapy
and/or surgery, have considerably improved patients’
overall survival and quality of life, many cancers remain
incurable and unmanageable. Therefore, there is a need
to develop safe and effective anti-cancer agents [2].
Recently, new technologies have been tested success-
fully. These include oncolytic virotherapy, in which cer-
tain viruses selectively infect and kill cancerous cells,
leaving normal cells unharmed in vitro [3-6] and in
xenografted mice in vivo [7-9].
Myxoma virus (MV) is a rabbit-specific poxvirus
pathogen that in the past few years has been intensely
investigated as a potential oncolytic candidate [10-13].
MV is non-pathogenic in humans and has the benefit of
being able to selectively target and terminate a wide
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range (about 70%) of human cancerous cells [14]. Fur-
thermore, in vitro investigations into MV show its ability
to infect immortalized baby green monkey kidney
(BGMK) cells and some primary human dermal fibro-
blasts [14]. The mechanism of how MV selects and tar-
gets malignant cells is believed to be related to a unique
tropism associated with the dysregulated intracellular
signalling pathways, found in the majority of human
cancers such as the Akt pathway [3]. Cell transformation
and oncogenic activity is linked to the kinase activity of
Akt. Hence, proliferation of tumor cells results from
the dysregulation of Akt activity [15,16]. It has been
reported that Akt needs to be activated via interaction
with a viral ankyrin-repeat host range factor before MV
can infect human cancer cells [17].
Akt, or protein kinase B (PKB), is a serine/threonine
kinase that plays a crucial role in the regulation of many
cellular processes, including apoptosis or programmed
cell death, proliferation, angiogenesis and metabolism
[13,18-20]. It is activated via the phosphorylation of its
central components ser-473/474 and thr-308/309 [21].
Akt can be upregulated by a range of biological stimuli,
including growth factors, protein phosphatase inhibitors
and phosphatidylinositol 3-kinase (PI3K) [22].
The resonant recognition model (RRM) is a novel ap-
proach to de novo design of therapeutic peptides [23]. It
is a physico-mathematical model used for analysing pro-
tein structure and function; predicting protein active
binding sites and functional mutagenesis; and protein ac-
tivation using the applied electromagnetic radiation
(EMR) of the defined frequency [24,25]. The RRM con-
cept is based on the finding that protein biological func-
tion is characterised by certain periodicities (frequencies)
in the distribution of electron-free energy along the pro-
tein sequence. By utilizing this approach, it is possible to
predict key amino acids that can contribute to protein
activity and to design new peptides with the desired bio-
logical activity. It was suggested that these short, syn-
thetic peptides will have a high tissue penetration and
relatively low production cost, and can be easily modified
for improved bioavailability [24,26].
The bioactive peptide “RRM-MV” was computationally
designed by the RRM to mimic the bioactivity of
selected MV proteins. It is a linear, short peptide (18 aa;
MW 2.34 kDa), with an estimated half-life of 30 h in
mammalian reticulocytes [27]. A non-bioactive peptide
RRM-C (22 aa; MW 2.45 kDa) was also designed by
RRM as a negative control, with an estimated half-life of
1.2 h in mammalian cells [28].
Our previous study [27] demonstrated that RRM-MV
has a toxic effect on different types of mammalian tumor
cell lines, and that this bioactive peptide has targeted
and lethally harmed cancer cells, but left normal cells
unharmed. In the current study, we have extended the
evaluation of the toxic effect of RRM-MV and RRM-C
on transformed human skin cancer and normal cell lines
using qualitative and quantitative cellular viability, cyto-
toxicity and DNA fragmentations assays. We have also
investigated the effect of these two peptides on Akt cell
signalling pathway in human skin cancer and normal
cell lines.
Methods
Cell cultures
The human malignant melanoma cell line (MM96L),
human squamous cell carcinoma cell line (COLO-16),
normal human epidermal melanocytes cell line (HEM)
and normal human dermal fibroblast cell line (HDF)
were obtained from the School of Medical Sciences,
RMIT University, Australia. MM96L and COLO-16 cell
lines were cultured in Roswell Park Memorial Institute
medium (RPMI) 1640 (GIBCO, Australia) supplemented
with 10% heat-inactivated fetal bovine serum (FBS)
(Bovogen serumBiologicals, Australia). HEM cell line
was grown in medium 254, supplemented with 1%
human melanocyte growth supplement (HMGS) (Cas-
cade Biologics, Australia). HDF cell line was propagated
in medium 106 supplemented with 2% Low Serum
Growth Supplement (LSGS) (GIBCO, Australia).
RRM peptides preparation
The bioactive peptide RRM-MV and non-bioactive
(negative control) peptide RRM-C were designed as pre-
viously described [27]. They were specifically designed
with> 95% purity (AUSPEP, Melbourne, Australia).
RRM-MV (MW 2.34 kDa) and RRM-C (MW 2.45 kDa)
were freshly dissolved in either RPMI 1640, medium 254
or medium 106, according to the cell line used in the ex-
periment. Peptide stocks were then prepared at the fol-
lowing concentrations: 50 ng/mL (21.32 nM RRM-MV or
20.37 nM RRM-C), 100 ng/mL (42.6 nM RRM-MV or
40.7 nM RRM-C), 200 ng/mL (85.3 nM RRM-MV or 81.5
nM RRM-C), 400 ng/mL (170.5 nM RRM-MV or 162.9
nM RRM-C), 800 ng/mL (341 nM RRM-MV or 325.9 nM
RRM-C) and 1600 ng/mL (682 nM RRM-MV or 651.7
nM RRM-C).
Apoptosis and necrosis assay
The effects of the RRM-designed peptides on cellular
apoptosis and necrosis were determined by the apoptosis
and necrosis assay. Cells were stained with the Annexin
V-Alexa Fluor 488 (AF488) conjugate and Propidium
Iodide (PI) as described in the manufacturer's protocol
manual (Vybrant Apoptosis Assay kit II, Invitrogen,
USA), with minor modifications. In brief, the cells were
seeded at a density of 3 × 105 cell per well in a 24-well
plate and incubated overnight. Cells were treated with
100 ng/mL, 200 ng/mL and 400 ng/mL of RRM-MV or
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RRM-C, then incubated for 3 h or 18 h. After incuba-
tion, they were washed with cold phosphate-buffered sa-
line (PBS). To each sample, 5 μL of AF488 and 1.5 μL of
PI were added. These samples were then incubated at
room temperature for 20 min before being washed twice
and resuspended in a binding buffer (10 mM HEPES,
140 mM NaCl, 2.5 mM CaCl2 at pH 7.4). Stained cells
were kept protected from light until they were examined
by confocal laser scanning microscopy (CLSM). CLSM
images were taken at 10, 20 and 40 ×magnifications,
with the pinhole aperture set at 1 using Nikon Eclipse
Ti-E A1 laser-scanning confocal system (Nikon Instru-
ments Inc, Japan). Images were analysed with the NIS-
Element imaging software. All samples in duplicates
were tested at least three times in duplicates.
Lactate dehydrogenase (LDH) assay
The effect of the bioactive peptide RRM-MV on cell
cytotoxicity was determined using the LDH assay. Cells
were seeded at a density of 3 × 105 cell per well in a
96-well plate and incubated overnight. They were then
treated in triplicate with 400 ng/mL of RRM-MV or
RRM-C and incubated for another 3 h. The LDH
released from damaged cells was measured by Cytotox-
icity Detection Kit (Roche Diagnostics, USA) according
to the manufacturer’s instructions. The background con-
trol values were subtracted from each well and the mean
percent treatment induced cytotoxicity for each cell line
was calculated using the following equation: 100 × [(ex-
perimental value – low control)/(high control – low con-
trol)], where:
low control =mean absorbance from the untreated
cells (spontaneous release of LDH) and high control =
mean absorbance from lysis cells (maximum release of
LDH) (positive control).
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium
bromide) cell viability assay
The effect of the RRM-designed peptides on cell viability
was determined using the MTT assay as described by
Mosmann [29]. Briefly, cells were seeded at 3 × 105 cells
per well, in a 96-well plate and incubated overnight.
Cells were then treated with 100 ng/mL, 200 ng/mL,
400 ng/mL, 600 ng/mL, 800 ng/mL, 1000 ng/mL,
1200 ng/mL, 1400 ng/mL and 1600 ng/mL of the RRM-
designed peptide for 3 h incubation, or 25 ng/mL,
50 ng/mL, 100 ng/mL, 200 ng/mL, 400 ng/mL, 600 ng/
mL and 800 ng/mL) for 18 h incubation. Followed by
adding 25μL of the MTT solution (5 mg/mL; Sigma-
Aldrich Company, St. Louis, MO), while cells were pro-
tected from light. After 4 h incubation, under standard
conditions of 5% CO2 and 37 °C, the purple formazan
product became visible. The precipitated formazan was
dissolved by adding 100 μL dimethyl sulfoxide (DMSO)
(Millipore, France) and placing it on a shaker for 5 min-
utes. The absorbance was read on ELISA plate reader
(Thermo Electron Corporation, USA) at 595 nm. The
blank values (medium) were subtracted from each well
of the untreated and treated cells. The results were
reported as percentage of cell death where the OD
measure from untreated cells was considered to be 0%
of cell death. The percentage of cell death was calculated
as [1 – (OD 595 nm experiment/OD 595 nm untreated
cells)] × 100.
DNA fragmentation assay
DNA fragmentation assay was used to evaluate the effect
of RRM-MV on DNA fragmentation in skin cancer cells.
Cells were grown in a six-well plate at a density of
7 × 105 cell per well and incubated overnight. MM96L
and COLO-16 cells were incubated with 200 ng/mL and
400 ng/mL RRM-MV or RRM-C for 18 h. Following in-
cubation, DNA was extracted using a WizardW Genomic
DNA Purification Kit (Promega, Australia) according to
the manufacturer’s protocol. DNA concentration was
quantified using a spectrophotometer at 260 nm and
280 nm. DNA was detected by agarose gel electrophor-
esis on a 1.5% agarose gel at 100 V for 1 h. Gels were
stained with 3 μg/mL of ethidium bromide and visualized
under ultraviolet light using the BioRad Gel Doc system.
Immuno-blots for Akt Phosphorylation
Total Akt and p-Akt were detected by immuno-blotting
to determine the effect of RRM-designed peptides on
Akt pathway in human skin cancer and normal human
skin cells.
Antibodies and reagents
Rabbit monoclonal p-Akt (Ser-473) (D9E) XP antibody,
rabbit monoclonal p-Akt (Thr308) (C31E5E) antibody,
and rabbit polyclonal Akt (pan) (C67E7) primary anti-
body were all purchased from Cell Signaling Technology,
Inc. (Beverly MA, USA). The alkaline phosphatase-
conjugated goat anti-rabbit polyclonal secondary anti-
body was obtained from Sapphire Bioscience, Australia.
Protein extraction
Cells were seeded at a density of 7 × 105 cell per well
in a six-well plate in complete growth medium with
10% FBS and incubated overnight. Cells were then trea-
ted with 400 ng/mL of RRM-designed peptide and
incubated for 3 h. Cells were washed twice with cold
PBS. After treatment, PhosphoSafe™ Extraction reagent
(Novagen, USA) mixed with Protease Inhibitor Cock-
tails (Sigma-Aldrich, USA) was added and the plate
was incubated for 10 min at room temperature. Cells
were scraped and centrifuged at 16,000 xg for 5 min at
4 °C. The supernatants were collected and the protein
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concentration was quantified by the Bradford method
as previously described [30] using bovine serum albu-
min (BSA) as a standard.
Immuno-blot analysis
Equal amounts of protein (30 μg per lane) from each
sample were resolved on 12.5% SDS-polyacrylamide gel
electrophoresis using Mini-PROTEAN Tetra Cell elec-
trophoresis system (Bio-Rad, USA). iBlot Dry Blotting
System (Invitrogen, USA) was used to transfer the pro-
tein from the gel to nitrocellulose membrane. Western
blotting was carried out as described [3] with some
modifications. The immune bands were detected using
5-Bromo-4-chloro-3-indolyl phosphate toluidine salt/
Nitro blue tetrazolium chloride (BCIP/NBT) substrate
solution (Amresco, USA) with detection buffer (100 mM
Tris, 100 Mm NaCl at pH 9.5) (v/v). Membranes were
incubated until full colour development occurred. Reac-
tion was stopped by washing in distilled water for 5 min
prior to being dried.
Hemolysis assay
The hemolytic effect of the RRM-designed peptides on
human erythrocytes was carried out in a 96 well plate as
described [31] with minor modifications. In brief, 5 mL
fresh, whole blood was collected from an antecubital
vein using a 21-gauge needle into EDTA tube. The blood
was then diluted 1:5 with PBS and centrifuged at 1000
xg for 10 min. The erythrocytes pellet was resuspended
in PBS to a final concentration of 3% (v/v). The erythro-
cytes suspension was treated with an equal volume of
RRM-MV or RRM-C at the following concentrations:
50 ng/mL, 100 ng/mL, 200 ng/mL, 400 ng/mL, 600 ng/
mL, 800 ng/mL, 1000 ng/mL, 1200 ng/mL, 1400 ng/mL
and 1600 ng/mL. A completely lysed erythrocyte pellet
was used as a positive control. The erythrocytes pellet
was resuspended in sterile distilled water to a final con-
centration of 3% (v/v) for complete lysis. Following incu-
bation at 37 °C overnight, the plate was centrifuged at
1000 xg for 10 min. The supernatants were collected
and the OD at 595 nm was measured using ELISA plate
reader (Thermo Electron Corporation, USA).
Statistical analysis
Statistical analysis was performed using the Microsoft
Office 2003 Excel software (Microsoft Corporation, Red-
mond Washington USA) and SPSS statistical software
(version 18.0, SPSS, Inc., Chicago, IL, USA). The statis-
tical significance of the differences between treated
groups, controls groups and untreated groups were ana-
lyzed by one-way ANOVA and Tukey post hoc test.
Experiments were performed at least three times inde-
pendently. All values are expressed as mean ± standard
errors. Results were considered significant at P< 0.05.
Results
Detection of cellular apoptosis and necrosis
The cytotoxic effects of RRM-MV and RRM-C were
detected on the human cancer cell lines (MM96L and
COLO-16) at different concentrations and different incu-
bation times using CLSM. The characteristic morpho-
logical changes associated with apoptosis and/or necrosis
were observed in these cell lines after RRM-MV treat-
ment. Incubation of MM96L with 100 ng/mL of RRM-
MV for 3 h induced slight apoptotic or necrotic effects
which were not seen in RRM-C-treated and untreated
cells (Figure 1A). Conversely, prolonged incubation of up
to 18 h at this concentration caused significant apoptotic
and necrotic effects in MM96L which were not seen in
RRM-C-treated and untreated cells (Figure 1B). Similar
effects were observed when the COLO-16 cell line was
treated with 100 ng/mL of RRM-MV for 3 h (Figure 2) or
for 18 h.
Treatment with higher concentrations (200 ng/mL
and 400 ng/mL) of RRM-MV produced significant
apoptotic and necrotic effects and detachment in
MM96L and COLO-16 cell lines after only 3 h of incu-
bation (Figure 1A and 2, respectively). Interestingly, no
significant cytotoxic effects were detected when MM96L
and COLO-16 cells were treated with similar concentra-
tions of the negative control peptide RRM-C for 3 h
and 18 h.
Cellular apoptosis and/or necrosis were also assessed
by CLSM in normal human skin cell lines (HEM and
HDF). These cell lines were treated with 200 ng/mL and
400 ng/mL of RRM-MV or with similar concentrations
of RRM-C. After 3 h of incubation, the CLSM micro-
graphs indicated that neither apoptotic nor necrotic
effects were observed in HEM and HDF cell lines treated
with RRM-MV (Figure 3A and 3B, respectively). Taken
together, no significant cytotoxic effects were observed
on these cell lines after treatment either with RRM-MV
or RRM-C.
Treatment with RRM-MV induced lactate dehydrogenase
(LDH) release
Quantification of LDH activity released from damaged
cells was measured using the LDH assay. The ability of
the RRM-MV to induce LDH release from MM96L,
COLO-16, HEM and HDF cell lines was investigated.
Cells were incubated with 400 ng/mL of RRM-MV or
RRM-C for 3 h. Data analysis of results revealed that
the release of LDH from cells into the culture medium
increased significantly after 3 h in RRM-MV-treated
cancer cells compared with untreated cells. This sug-
gested that treatment with 400 ng/mL of RRM-MV
caused plasma membrane rupture and cellular damage
in cancer cells. However, in normal cells, there was no
significant difference in LDH release between RRM-
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Figure 1 CLSM micrographs of apoptosis and/or necrosis in malignant melanoma cell line (MM96L). Cells were incubated for 3 h with
100 ng/mL, 200 ng/mL or 400 ng/mL of RRM-MV or RRM-C in (A); or with 100 ng/mL of RRM-MV or RRM-C for 18 h in (B). After incubation, cells
were double stained with AF488 and PI. CLSM images show that RRM-MV induced cell apoptosis/necrosis effects. Prolonged incubation with
RRM-MV caused stronger cytotoxic effects. AF488 channels show apoptotic cells labeled with green-fluorescent, and PI channels show necrotic
cells labeled with red-fluorescent. CLSM images were taken with Nikon Eclipse Ti-E A1 laser-scanning confocal system, and analysed with the
NIS-Element imaging software (100x magnification).
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MV-treated and untreated cells. Interestingly, RRM-C
treatment did not induce significant LDH releases and
was non-toxic for all tested cell lines (Figure 4). In
total, the results indicated that the plasma membrane
of the two normal cell lines remained intact during in-
cubation with either the bioactive peptide RRM-MV or
non-bioactive peptide RRM-C. Yet, RRM-MV treatment
significantly induced cytotoxicity in cancer cells.
RRM-MV induces cell death in dose and time-dependent
manners in carcinoma and melanoma cell lines
The effects of different doses and incubation periods of
RRM-MV or RRM-C on cell death were determined in
MM96L and COLO-16 cell lines using the MTT cell
viability assay. Cells were treated with different concen-
trations of peptides for 3 h or 18 h. Cancer cells were
treated with (100 ng/mL, 200 ng/mL, 400 ng/mL,
600 ng/mL, 800 ng/mL, 1000 ng/mL, 1200 ng/mL,
1400 ng/mL and 1600 ng/mL) of either RRM-MV or
RRM-C for 3 h. Data analysis of results indicated that
cell death in MM96L and COLO16 increased noticeably
with higher doses of RRM-MV compared with RRM-C-
treated and untreated cells (p <0.001) in both cell lines.
The maximum percentage of cell death was 34.92% and
57.98% at 1600 ng/mL of RRM-MV in MM96L and
COLO-16 cell lines, respectively (Figure 5A and 5B).
Additionally, incubation of cells with 25 ng/mL, 50 ng/
mL, 100 ng/mL, 200 ng/mL, 400 ng/mL and 800 ng/mL
RRM-MV for 18 h caused a statistically significant re-
duction in cell viability. At the highest peptide concen-
tration (800 ng/mL RRM-MV), the percentage of cell
death was 52.9% and 59.95% in MM96L and COLO-16
cell lines respectively (p <0.001 in MM96L and
COLO16). Interestingly, RRM-C treatment for either 3 h
or 18 h in both cell lines had negligible effects on cell via-
bility even at the highest concentrations used (1600 ng/
mL) (Figure 6A and 6B). Cytotoxic responses against
RRM-MV treatment substantially increased in the cancer
Figure 2 CLSM images of apoptosis and/or necrosis in human squamous cell carcinoma (COLO-16) cell line. Cells were incubated for 3 h
with 100 ng/mL, 200 ng/mL or 400 ng/mL of RRM-MV or RRM-C. After incubation, cells were double stained with AF488 and PI. These CLSM
images show that RRM-MV induced cell apoptosis/necrosis effects. AF488 channels show apoptotic cells labeled with green-fluorescent and PI
channels show necrotic cells labeled with red-fluorescent (100x magnification).
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cells with increased doses. Hence, RRM-MV treatment
decreased cell survival through the induction of cell
death in dose- and time-dependent manners within 18 h.
However, treatment of cancer cells with RRM-C dis-
played minimal effects on the tested cancer cell lines.
The RRM-MV had no effect on cell viability in the normal
human skin cell line (HDF)
HDF human skin cell line was incubated with RRM-MV
or RRM-C 100 ng/mL, 200 ng/mL, 400 ng/mL, 800 ng/
mL and 1600 ng/mL for 3 h, and 100 ng/mL, 200 ng/
Figure 3 CLSM images of normal human epidermal melanocytes (HEM) and normal human dermal fibroblast (HDF) cell lines following
incubation with RRM-MV or RRM-C. HEM cells in (A) and HDF cells in (B) were treated with 200 ng/mL or 400 ng/mL of either RRM-MV or
RRM-C for 3 h, then double stained with AF488 and PI. No cytotoxic changes were detected in either cell line treated with RRM-MV.
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mL, 400 ng/mL and 800 ng/mL for 18 h. Toxic effects
of these peptides were evaluated by MTT assay. There
appeared to be no significant difference in HDF viability
between RRM-MV-treated and untreated cells. No sig-
nificant loss in viability was observed with RRM-C treat-
ment (Figures 5C and 6C). Data analysis of results
indicated that even the highest concentration of peptides
treatment had negligible toxic effects on the tested nor-
mal human skin cells.
RRM-MV induced DNA degradation in human skin cancer
cell lines
DNA fragmentation was analysed by agarose gel electro-
phoresis to detect apoptosis in human skin cancer cells.
MM96L and COLO-16 cell lines were incubated with
(200 ng/mL and 400 ng/mL) of RRM-MV or RRM-C for
18 h. Agarose gel analysis showed that RRM-MV treat-
ment clearly degraded DNA at both peptide concentra-
tions, in contrast with the untreated controls in MM96L
cell line (Figure 7A, lane 4 and 6). Conversely, DNA
degradation could not be observed in RRM-MV-treated
COLO-16 cell line at similar concentrations within the
Figure 4 Cytotoxic effects measured by LDH enzymatic activity
in human skin cancer and normal human skin cells after
treatment with RRM-MV or RRM-C. LDH levels were measured
following treatment with 400 ng/mL of RRM-MV or RRM-C for 3 h.
RRM-MV produced high cellular LDH levels in cancer cells. Results
are average of three independent experiments. Cytotoxicity values
were analysed using one-way ANOVA and Tukey post hoc test. They
showed a significant difference between RRM-MV-treated cells and
untreated cells (p< 0.01). Significant values are indicated with an *.
Figure 5 Cellular viability of human skin cancer and normal human skin cell lines treated with RRM-designed peptides for 3 h
measured by MTT assay. MM96L cells in (A), COLO-16 cells in (B), and HDF cells in (C) were incubated with different concentrations of RRM-MV
or RRM-C for 3 h. Cells treated with 90% DMSO were used as positive controls. Results are reported as percentage of cell death, where the optical
density (OD595nm) value from untreated cells was set at 0% of cell death. The bar graphs show mean± standard error of three independent
experiments. Statistical significance of the differences between RRM-MV-treated cells and untreated cells were analysed using one-way ANOVA
and Tukey post hoc test. The cellular viability values of RRM-MV-treated melanoma and carcinoma cells were significantly different from those of
untreated melanoma and carcinoma cells (P< 0.001).
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Figure 6 Cellular viability of human skin cancer and normal human skin cell lines treated with RRM-designed peptides for 18 h
measured by MTT assay. MM96L cells in (A), COLO-16 cells in (B), and HDF cells in (C) were treated with different concentrations of RRM-MV or
RRM-C for 18 h. Cells from each cell line were treated with 90% DMSO and used as positive controls. The effect of the peptides on cell viability
was determined by MTT assay. Results are reported as percentage of cell death, where the optical density (OD) value from untreated cells was set
at 0% of cell death. Bars indicate the mean± standard error of three independent experiments. Statistical evaluation was performed by using
one-way ANOVA and Tukey post hoc test. The RRM-MV-treated cancer cells were significantly different from untreated cells (P< 0.001).
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same duration (Figure 7B, lane 4 and 6). The RRM-C
treatment caused no changes in DNA patterns in
MM96L and COLO-16 cell lines. Taken together, the
RRM-MV treatment induced DNA degradation in mel-
anoma cells which is the biochemical hallmark of apop-
totic cell death, however, this degradation could not be
observed in carcinoma cells.
The effect of RRM-MV on the Akt signalling pathway
The effect of RRM-MV or RRM-C treatment on Akt sig-
nalling pathways in MM96L, COLO-16 and HDF cell
lines was investigated using immuno-blotting. All cell
lines were incubated with RRM-MV or RRM-C for 3 h
at the concentration of 400 ng/mL. Western blot results
indicated that the immune band intensities of phospho-
Akt at (Thr-308 and p-Akt Ser-473) were slightly
increased in MM96L and COLO-16 cells after RRM-MV
treatement (Figure 8A, lanes 3 and 6, respectively).
However, there was also no difference in the intensity of
the immune bands for p-Akt at (Thr-308 and p-Akt Ser-
473) and total Akt in the HDF cell line after RRM-MV
treatment (Figure 8B, lane 3). The RRM-C treatment did
not seem to affect the intensity of the immune bands of
p-Akt and total Akt in tested cell lines as compared with
untreated cells (Figure 8A and B). Taken together, the
RRM-MV treatment did not appear to significantly affect
the expression of Akt in HDF cell lines; however, there
was a slight increase in the expression of p-Akt in the
RRM-MV-treated MM96L and COLO16 cell lines.
Effect of RRM-designed peptides on human erythrocytes
The toxicity of RRM-MV on human erythrocytes was
tested using the hemolysis assay to evaluate the suitabil-
ity of RRM-MV as a future therapeutic agent. Human
erythrocytes were incubated with various concentrations
of RRM-MV (50 ng/mL, 100 ng/mL, 200 ng/mL, 400 ng/
mL, 600 ng/mL, 800 ng/mL, 1000 ng/mL, 1200 ng/mL,
1400 ng/mL and 1600 ng/mL) for 18 h. Similar concen-
trations of RRM-C were also tested on human erythro-
cytes for comparison. Results indicated that treatment of
human erythrocytes with RRM-MV or RRM-C did not
induce erythrocytes lysis at any of the concentrations
used when compared with the complete erythrocyte lysis
positive control (Figure 9). Thus, human erythrocytes
appeared to be relatively resistant to RRM-MV and
RRM-C treatments.
Discussion
Peptide therapy has been applied in developing potential
cancer therapeutics. These therapies focus on short pep-
tide with strong tumoricidal activity and low toxicity
[23,28,32,33]. We recently applied the RRM approach to
design a short linear bioactive peptide (RRM-MV),
mimicking the bioactivity of specific MV proteins. The
RRM-MV has selectively potent antitumour cytotoxic
effects on mouse melanoma in vitro in dose- and time-
dependent manners [27]. We also used RRM to design
the peptide analogue IL-12 to mimic the activity of
mouse interlukin-12. This peptide produced cytotoxic
effect on the B16F0 mouse melanoma cancer cells
(B16F0) [33].
The current study examined and evaluated the suit-
ability of RRM-MV as a candidate for human skin cancer
therapy. The toxic effects of RRM-MV on the viability of
human skin cancer and normal human skin cell lines
were investigated. We found that RRM-MV induced
apoptotic/necrotic effects in dose- and time-dependent
manners in MM96L melanoma and COLO-16 carcin-
oma cell lines. We used AF488 and PI to detect apop-
tosis/necrosis in the plasma membrane. Early apoptotic
cells were detected after 3 h of incubation with 200 ng/
mL and 400 ng/mL RRM-MV. There were also many
more apoptotic/necrotic cells to live cells in the RRM-
MV-treated cancer cell lines when compared with the
same ratio in RRM-C-treated and untreated cancer cell
lines. When cancer cells were incubated with RRM-MV
for a longer period (18 h), this bioactive peptide had a
significant cytotoxic effect on these cells. In contrast,
Figure 7 Effect of RRM-MV treatment on the DNA of cancer cell
lines. MM96L cells in (A) and COLO16 cells in (B) were incubated
with 200 and 400 ng/mL of RRM-C or RRM-MV for 18 h. DNA was
extracted and analyzed by electrophoresis on 1.5% agarose gel with
ethidium bromide staining. DNA samples are labeled as: (M)
molecular weight marker, (1) untreated cells, (2) cells treated with
DMSO as positive controls, (3) cells treated with 200 ng/mL RRM-C,
(4) cells treated with 200 ng/mL RRM-MV, (5) cells treated with
400 ng/mL RRM-C, and (6) RRM-MV-treated cells. In MM96L cells,
RRM-MV treatment produced DNA degradation, whereas in COLO16
cells, DNA degradation was not detected even with DMSO-treated
samples. Results are representative of more than three independent
experiments.
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normal human skin cells were not affected by RRM-MV
when incubated with it under similar conditions. Our
findings suggest that the bioactive peptide RRM-MV can
successfully induce apoptosis and necrosis in melanoma
and carcinoma cells.
Moreover, this study showed that the level of LDH
released from the RRM-MV-treated cancer cells was
significantly higher (p< 0.01) than that released from
untreated cells. The raise in LDH levels is known to be
caused by an increased amount of dead cells or plasma
membrane damage [29,34]. Our findings suggest that
RRM-MV caused plasma membrane damage leading to
a greater cytotoxic effect on cancer cells, but not on
normal cells.
Increased LDH release was also confirmed by examin-
ing mitochondrial activity using MTT assay. Our data
indicated that RRM-MV displayed significant cytotox-
icity (P< 0.001) towards human skin cancer cells. Incu-
bation with higher concentrations (up to 1600 ng/mL) of
RRM-MV damaged cellular structures and made cells
enter the necrotic death pathway, evident by the analysis
of the cells’ morphology and increased LDH release with
reduction in cell viability. On the other hand, in normal
human skin cells neither RRM-MV nor RRM-C
increased cell death within the investigated concentra-
tion range. This showed that the bioactive peptide has a
negligible toxic effect on normal human skin cells, but
high cytotoxicity towards cancer cells. In addition, the
Figure 8 The effect of RRM-designed peptides on cellular expression of p-Akt and total Akt. Western blots for cancer cell lines MM96L
and COLO-16 are presented in (A) and HDF cell line in (B) as indicated below the WB. Cell lysates were prepared and immune-blotted using
p-Akt (Ser473), p-Akt (Thr308) and total Akt antibodies (around 60 kDa). The WBs show that RRM-MV treatment slightly affected p-Akt expression
in the MM96L and COLO-16 cell lines, but did not affect the expression of p-Akt or total Akt in HDF cell line. These figures are derived from
multiple immuno-blotting experiments.
Figure 9 The effect of the RRM-designed peptides on human erythrocytes. Washed human erythrocytes in PBS were incubated for 18 h
with the following concentrations of RRM-MVor RRM-C: 50 ng/mL; 100 ng/mL; 200 ng/mL; 400 ng/mL; 600 ng/mL; 800 ng/mL; 100 ng/mL;
1200 ng/mL; 1400 ng/mL; and1600 ng/mL. Human red blood cells were relatively resistant to RRM-MV and RRM-C treatment when incubated for
up to 18 h, as cytolytic/hemolytic effects were not detected after treatment with both peptides. Data values are the average of three
independent experiments in triplicates.
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dose- and time-response study revealed that high con-
centration treatments (above 400 ng/mL) caused the
greatest cytotoxic responses. This supported our previ-
ous findings that RRM-MV has cytotoxic effects in a
variety of mammalian tumor cell lines [27,28]. Our data
also showed that RRM-MV has minimal cytotoxicity on
normal human skin cells even at high concentrations.
The apoptotic effect of RRM-MV was further con-
firmed by the DNA fragmentation assay. RRM-MV-
treatment extensively degraded DNA in melanoma cells,
suggesting that cells treated with RRM-MV underwent
apoptosis. Normally, DNA degradation is considered a
biochemical hallmark of apoptosis that involves cutting
the inter-nucleosomal regions into small fragments of
double-stranded DNA [35-37]. Thus, changing in the
DNA characteristics after RRM-MV treatment con-
firmed cell death induction in melanoma cells. However,
DNA degradation was not noticed in the RRM-MV-
treated carcinoma cell line, although cellular cytotoxicity
was confirmed by CLSM, LDH and MTT assays. This
could be explained by the lack of endogenous DNases in
this cell line [36]. Therefore, the potential of cells under-
going early apoptosis can not be eliminated in this cell
line by the non-appearance of DNA degradation [38-40].
We also investigated if the Akt signalling pathway is
targeted by RRM-MV as a possible cell death pathway in
human skin cancer cells. It is believed that regulation of
Akt activation is impaired in cancer cells [3], yet in some
human cancer cells, it was shown that M-T5 protein of
MV binds to p-Akt to regulate Akt signalling [41]. Data
from this study indicated that the levels of p-Akt expres-
sion at Ser-473 and Thr-308 slightly increased in the
RRM-MV-treated melanoma and carcinoma cells. Levels
of p-Akt and total Akt were also unaffected by RRM-C
treatment in both cancer cell lines. Likewise, levels of p-
Akt and total Akt expression were unaffected after
RRM-MV or RRM-C treatment in the normal human
skin cell line. In our previous study we found that the
Akt signalling pathway did not seem to be affected by
RRM-MV treatment in the mouse melanoma cell line
(B16F0) [27]. Wang et al. [3] reported that Akt phos-
phorylation can be activated by forming a complex be-
tween the viral protein (M-T5) and Akt in MV-infected
permissive human cancer cell lines only.
Our study also showed that human erythrocytes were
relatively resistant to haemolysis when treated with
RRM-MV even at high concentrations. This supports
the suitability of RRM-MV as a potential antitumor
therapeutic agent.
Conclusions
We have previously shown that RRM-MV produced
toxic effects on the B16F0 mouse melanoma cell line.
Here, we found that RRM-MV has a selective pro-
apoptotic and cytotoxic activity on human melanoma
and carcinoma cells without significantly affecting nor-
mal cells. Treatment of these cells with RRM-MV caused
characteristic cellular morphology changes, apoptosis
and/or necrosis, reduced cellular viability and induced
cell membrane damage, while addition of the negative
control peptide RRM-C produced no cytotoxic changes
in these cells. Further research is currently undertaken
to determine the exact mechanism in which cancer cells
are affected by this bioactive peptide.
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